United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026
United Therapeutics Corporation Announces FDA Approval of the LungFX Device for Centralized Ex Vivo Lung Perfusion
United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial
United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
MannKind Announces Ralinepag Dry Powder Inhalation Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
Bold Reports Positive Results of Induced Polarization Survey at Joutel - Signs Investor Awareness Agreement
SAGA Metals Highlights Historic $70 Billion Clean Energy Investment and Strategic Infrastructure Commitments in Labrador
Prince Silver Builds Momentum Toward Maiden Mineral Resource Estimate After Completing More than 10,000 m of Drilling
